Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 17/20 | 0.68 |
| ▸ | ADCY8 | P40145 | 12/20 | 0.68 |
| ▸ | HTR2B | P41595 | 2/20 | 0.66 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20673066 | 0.93 | ADCY1 (0.79) | ADCY1ADCY8HTR2B | |
| SCHEMBL20673148 | 0.88 | ADCY1 (0.62) | ADCY1ADCY8HTR2BSLC2A1MAPT | |
| SCHEMBL20673133 | 0.87 | ADCY1 (0.86) | ADCY1ADCY8HTR2BSLC2A1 | |
| SCHEMBL20673024 | 0.86 | ADCY1 (0.71) | ADCY1ADCY8HTR2BSLC2A1 | |
| SCHEMBL20673129 | 0.85 | ADCY1 (0.85) | ADCY1ADCY8HTR2BSLC2A1 | |
| SCHEMBL20673246 | 0.84 | ADCY1 (0.56) | ADCY1ADCY8HTR2BSLC2A1MAPT | |
| SCHEMBL20673244 | 0.84 | ADCY1 (0.58) | ADCY1ADCY8HTR2BSLC2A1MAPT | |
| SCHEMBL23188255 | 0.81 | ADCY1 (1.00) | ADCY1ADCY8HTR2B | |
| SCHEMBL23188313 | 0.81 | ADCY1 (1.00) | ADCY1ADCY8HTR2B | |
| SCHEMBL20673073 | 0.81 | SLC2A1 (0.62) | ADCY1ADCY8HTR2BSLC2A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667623-B2 | Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence | PURDUE RESEARCH FOUNDATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667623-B2 | Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence | PURDUE RESEARCH FOUNDATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-20200239447-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | PURDUE RESEARCH FOUNDATION (US) | 2020-07-30 | — | — | US | disclosed |
| US-10662176-B2 | Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence | PURDUE RESEARCH FOUNDATION (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190023688-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | PURDUE RESEARCH FOUNDATION (US) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239447-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | CAP1, ADCY1, ADCYAP1R1 | ADCY1 2/4885ADCY8 7/4885HTR2B 2025/4885 |
| US-20190023688-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | CAP1, ADCY1, ADCYAP1R1 | ADCY1 2/4885ADCY8 7/4885HTR2B 2025/4885 |
| US-11667623-B2 | Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence | CAP1, ADCY1, ADCYAP1R1 | ADCY1 2/4885ADCY8 11/4885HTR2B 1794/4885 |
| US-10662176-B2 | Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence | CAP1, ADCY1, ADCYAP1R1 | ADCY1 2/4885ADCY8 11/4885HTR2B 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.